| |
| |
|
| Insider
Information: |
Spiegelman Daniel K |
| Relationship: |
Director |
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
155,668 |
|
|
Indirect Shares
|
6,673 |
|
|
| Direct
Value |
$5,014,809 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
162,341 |
|
|
| Total
Value |
$5,014,809 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
CV Therapeutics Inc |
CVTX |
SVP, CFO |
2009-04-09 |
67,489 |
2009-04-09 |
6,673 |
Premium* |
|
|
Cascadian Therapeutics, Inc |
CASC |
Director |
2018-03-09 |
0 |
2009-12-04 |
0 |
Premium* |
|
|
Biomarin Pharmaceutical Inc |
BMRN |
EVP, Chief Financial O... |
2019-04-30 |
47,686 |
2012-05-29 |
0 |
Premium* |
|
|
Relypsa Inc |
RLYP |
Director |
2016-09-01 |
0 |
2015-06-04 |
0 |
Premium* |
|
|
Myriad Genetics Inc |
MYGN |
Director |
2023-06-02 |
40,493 |
2020-05-27 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
180 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 8
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| CVTX |
CV Therapeutics Inc |
officerTitle |
• – – |
2003-06-26 |
4 |
GD |
$0.00 |
$0 |
D/D |
84 |
19,481 |
|
- |
|
| CVTX |
CV Therapeutics Inc |
Senior Vice President and CFO |
• – – |
2003-12-16 |
4 |
GD |
$0.00 |
$0 |
D/D |
200 |
20,480 |
|
- |
|
| CVTX |
CV Therapeutics Inc |
SVP, CFO |
• – – |
2005-08-25 |
4 |
GD |
$0.00 |
$0 |
D/D |
325 |
21,506 |
|
- |
|
| CVTX |
CV Therapeutics Inc |
SVP, CFO |
• – – |
2006-01-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
121 |
937 |
0 |
- |
|
| CVTX |
CV Therapeutics Inc |
SVP, CFO |
• – – |
2006-12-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
8,226 |
0 |
- |
|
| CVTX |
CV Therapeutics Inc |
SVP, CFO |
• – – |
2006-12-22 |
4 |
GD |
$0.00 |
$0 |
D/D |
400 |
11,386 |
0 |
- |
|
| CVTX |
CV Therapeutics Inc |
SVP, CFO |
• – – |
2007-01-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,732 |
11,884 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2009-12-04 |
4 |
A |
$0.00 |
$0 |
D/D |
6,185 |
6,185 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2010-06-03 |
4 |
A |
$0.00 |
$0 |
D/D |
8,086 |
14,271 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2011-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
4,538 |
18,809 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2011-06-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,076 |
20,885 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2012-05-29 |
4 |
A |
$0.00 |
$0 |
D/D |
33,000 |
33,000 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2013-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
13,200 |
46,200 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2014-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
26,250 |
64,273 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2014-03-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
19,352 |
43,709 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2014-06-04 |
4 |
A |
$0.00 |
$0 |
D/D |
13,800 |
73,134 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2015-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
10,500 |
79,278 |
0 |
- |
|
| RLYP |
Relypsa Inc |
Director |
– • – |
2015-06-04 |
4 |
A |
$0.00 |
$0 |
D/D |
2,250 |
2,250 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2015-06-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,042 |
56,686 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2016-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
72,633 |
101,077 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2016-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
16,640 |
63,933 |
0 |
- |
|
| CASC |
Cascadian Therapeutics, I... |
Director |
– • – |
2016-06-06 |
5 |
OE |
$0.00 |
$0 |
D/D |
2,723 |
11,502 |
0 |
- |
|
| RLYP |
Relypsa Inc |
Director |
– • – |
2016-06-21 |
4 |
A |
$0.00 |
$0 |
D/D |
2,250 |
3,487 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2017-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
12,247 |
30,347 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2017-03-22 |
4 |
A |
$0.00 |
$0 |
D/D |
12,200 |
26,671 |
0 |
- |
|
180 Records found
|
|
Page 1 of 8 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
